## oasmia

## Communiqué from annual general meeting

The general annual meeting of Oasmia Pharmaceutical AB was held on September $7^{\text {th }}, 2007$. At the meeting all members of the board were re-elected as follows: Claes Pihl, Julian Aleksov, Peter Ström and Bo Cederstrand. The board elected Bo Cederstrand as chairman.

The meeting adopted the board's proposal of a private placement, item 10 on the agenda.
The board's proposal of decision of private placement (item 10)
The company share capital amounts currently to 3185131 SEK, distributed over 31851310 shares in total. The board proposes that an increase in share capital with 152369 SEK by private placement of series a shares be carried out on the terms below:

1. The new shares shall be subscribed with differing preferential rights of share holders representatives' rights of Oasmia SA Luxembourg.
2. For every share an amount of 40.10 SEK shall be paid, where 40 SEK is premium.
3. Share subscription and offsets shall at the latest be performed by October $15^{\text {th }} 2007$.
4. The new shares shall give entitlement to dividends from the current fiscal year. Chief Executive Officer Julian Aleksov stated at the meeting that the annual report can be read in its entirety on www.oasmia.com

Uppsala, September $10^{\text {th }}, 2007$
Oasmia Pharmaceutical AB (PUBL)
The board

